Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Rex Fang & Innovation Equity Premium Income ETFTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Rex Fang & Innovation Equity Premium Income ETF vs Recursion Pharmaceuticals Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.87, while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Rex Fang & Innovation Equity Premium Income ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

FEPIRXRX
Sector
Income / Options OverlayHealth
52-Week High
$49.54$6.79
52-Week Low
$37.98$2.84
Market Cap
$1.78B
Enterprise Value
$1.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rex Fang & Innovation Equity Premium Income ETF

FEPI trades at $41.78, up 0.8% with a bullish technical signal from moving averages, though oscillators are neutral. The ETF provides a high yield through weekly dividends, recently transitioning to this frequency to enhance income compounding. Support and resistance are tightly clustered around $41-$42, indicating potential near-term consolidation.

Outlook: High income appeals but covered call strategy caps upside and risks NAV erosion in downturns. Opportunities include weekly cash flow for income-focused investors; risks involve concentrated tech exposure and market volatility. Analyst views are mixed, emphasizing accumulation on weakness.

Recursion Pharmaceuticals Inc

RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.

Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Rex Fang & Innovation Equity Premium Income ETF

FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.

Read more on FEPI

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX